AIM: To investigate the effects of the major component of high-density lipoprotein apolipoprotein A-I (apoA-I) on the development of atherosclerosis in LPS-challenged ApoE(-/-) mice and the underlying mechanisms. METHODS: Male ApoE-KO mice were daily injected with LPS (25 μg, sc) or PBS for 4 weeks. The LPS-challenged mice were intravenously injected with rAAV-apoA-I-GFP or rAAV-GFP. After the animals were killed, blood, livers and aortas were collected for biochemical and histological analyses. For ex vivo experiments, the abdominal cavity macrophages were harvested from each treatment group of mice, and cultured with autologous serum, then treated with LPS. RESULTS: Chronic administration of LPS in ApoE(-/-) mice significantly increased the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, and MCP-1), increased infiltration of inflammatory cells, and enhanced the development of atherosclerosis. In LPS-challenged mice injected with rAAV-apoA-I-GFP, viral particles and human apoA-I were detected in the livers, total plasma human apoA-I levels were grammatically increased; HDL-cholesterol level was significantly increased, TG and TC were slightly increased. Furthermore, overexpression of apoA-I significantly suppressed the expression of proinflammatory cytokines, reduced the infiltration of inflammatory cells, and decreased the extent of atherosclerotic lesions. Moreover, overexpression of apoA-I significantly increased the expression of the cytokine mRNA-destabilizing protein tristetraprolin (TTP), and phosphorylation of JAK2 and STAT3 in aortas. In ex vivo mouse macrophages, the serum from mice overexpressing apoA-I significantly increased the expression of TTP, accompanied by accelerated decay of mRNAs of the inflammatory cytokines. CONCLUSION: ApoA-I potently suppresses LPS-induced atherosclerosis by inhibiting the inflammatory response possibly via activation of STAT3 and upregulation of TTP.
AIM: To investigate the effects of the major component of high-density lipoprotein apolipoprotein A-I (apoA-I) on the development of atherosclerosis in LPS-challenged ApoE(-/-) mice and the underlying mechanisms. METHODS: Male ApoE-KO mice were daily injected with LPS (25 μg, sc) or PBS for 4 weeks. The LPS-challenged mice were intravenously injected with rAAV-apoA-I-GFP or rAAV-GFP. After the animals were killed, blood, livers and aortas were collected for biochemical and histological analyses. For ex vivo experiments, the abdominal cavity macrophages were harvested from each treatment group of mice, and cultured with autologous serum, then treated with LPS. RESULTS: Chronic administration of LPS in ApoE(-/-) mice significantly increased the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, and MCP-1), increased infiltration of inflammatory cells, and enhanced the development of atherosclerosis. In LPS-challenged mice injected with rAAV-apoA-I-GFP, viral particles and humanapoA-I were detected in the livers, total plasma humanapoA-I levels were grammatically increased; HDL-cholesterol level was significantly increased, TG and TC were slightly increased. Furthermore, overexpression of apoA-I significantly suppressed the expression of proinflammatory cytokines, reduced the infiltration of inflammatory cells, and decreased the extent of atherosclerotic lesions. Moreover, overexpression of apoA-I significantly increased the expression of the cytokine mRNA-destabilizing protein tristetraprolin (TTP), and phosphorylation of JAK2 and STAT3 in aortas. In ex vivo mouse macrophages, the serum from mice overexpressing apoA-I significantly increased the expression of TTP, accompanied by accelerated decay of mRNAs of the inflammatory cytokines. CONCLUSION:ApoA-I potently suppresses LPS-induced atherosclerosis by inhibiting the inflammatory response possibly via activation of STAT3 and upregulation of TTP.
Authors: Hye Jin Yoo; Sungeun Kim; Man Sik Park; Sae Jeong Yang; Tae Nyun Kim; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Hong Seog Seo; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi Journal: J Nucl Med Date: 2010-12-13 Impact factor: 10.057
Authors: Walter S Speidl; Giovanni Cimmino; Borja Ibanez; Sammy Elmariah; Randolph Hutter; Mario J Garcia; Valentin Fuster; Martin E Goldman; Juan J Badimon Journal: Eur Heart J Date: 2010-03-19 Impact factor: 29.983
Authors: Weiling Wang; Hao Xu; Yang Shi; Sandhya Nandedkar; Hao Zhang; Haiqing Gao; Thom Feroah; Dorothee Weihrauch; Marie L Schulte; Deron W Jones; Jason Jarzembowski; Mary Sorci-Thomas; Kirkwood A Pritchard Journal: J Lipid Res Date: 2010-05-24 Impact factor: 5.922
Authors: Kathleen A Smoak; Jim J Aloor; Jennifer Madenspacher; B Alex Merrick; Jennifer B Collins; Xuewei Zhu; Giorgio Cavigiolio; Michael N Oda; John S Parks; Michael B Fessler Journal: Cell Metab Date: 2010-06-09 Impact factor: 27.287
Authors: Bolormaa Vandanmagsar; Yun-Hee Youm; Anthony Ravussin; Jose E Galgani; Krisztian Stadler; Randall L Mynatt; Eric Ravussin; Jacqueline M Stephens; Vishwa Deep Dixit Journal: Nat Med Date: 2011-01-09 Impact factor: 53.440
Authors: Jessica P Otis; Meng-Chieh Shen; Blake A Caldwell; Oscar E Reyes Gaido; Steven A Farber Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-01-10 Impact factor: 4.052
Authors: Hagai Tavori; Yan Ru Su; Patricia G Yancey; Ilaria Giunzioni; Ashley J Wilhelm; John L Blakemore; Manal Zabalawi; MacRae F Linton; Mary G Sorci-Thomas; Sergio Fazio Journal: J Lipid Res Date: 2015-01-15 Impact factor: 5.922
Authors: Moritz von Scheidt; Yuqi Zhao; Thomas Q de Aguiar Vallim; Nam Che; Michael Wierer; Marcus M Seldin; Oscar Franzén; Zeyneb Kurt; Shichao Pang; Dario Bongiovanni; Masayuki Yamamoto; Peter A Edwards; Arno Ruusalepp; Jason C Kovacic; Matthias Mann; Johan L M Björkegren; Aldons J Lusis; Xia Yang; Heribert Schunkert Journal: Circulation Date: 2021-02-25 Impact factor: 29.690